Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms

Summary

To evaluate the safety and efficacy of tigecycline in the treatment of subjects with selected serious infections caused by resistant gram-negative bacteria, eg, Acinetobacter baumannii, Enterobacter species, Klebsiella pneumoniae or other resistant gram-negative pathogens, for whom antibiotics have failed or who cannot tolerate other appropriate antimicrobial therapies. The primary efficacy endpoint will be the clinical response.

Timeline

Start

2003-12

Primary completion

2005-11

Completion

2005-11

Drugs

Indications